Hetronifly is a cancer medicine used in adults to treat small cell lung cancer (SCLC) that has grown extensively in the lung or spread to other parts of the body (extensive-stage SCLC) and has not been treated previously. It is given together with carboplatin and etoposide (chemotherapy medicines). SCLC is rare, and Hetronifly was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 09 December 2022. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2731). Hetronifly contains the active substance serplulimab.
Therapeutic Indication
### Therapeutic indication Hetronifly in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Therapeutic Area (MeSH)
ATC Code
L01FF12
ATC Item
serplulimab
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Hetronifly
Medicine Name
Hetronifly
Aliases
N/ANo risk management plan link.
